Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 271

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 271
---
 2 eliminates the Class B Common Stock and increases the number of shares of authorized common stock;

• Dual-Class Capital Structure . The Pre-Closing Iris Certificate of Incorporation contains provisions regarding the conversion of Class B Common Stock and anti-dilution protections in respect of Class B Common Stock. The Pre-Closing Iris Certificate of Incorporation also requires the affirmative vote of the holders of a majority of the shares of Class B Common Stock in order to make any amendment that would

<div align='center'>131</div>

TABLE OF CONTENTS

alter or change the powers, preferences or other rights of the holders of Class B Common Stock. The ParentCo Certificate of Incorporation eliminates Class B Common Stock and any rights of holders thereof. Following the merger, the protections afforded the Class B Common Stock while Iris was a special purpose acquisition company will no longer be necessary. The Iris Board believes that the provisions relating to the Class B Common Stock will no longer be relevant to Liminatus and should be eliminated;

• Amendment . The amendment is intended to protect certain key provisions of the ParentCo Certificate of Incorporation from arbitrary amendment and to prevent a simple majority of stockholders from taking actions that may be harmful to other stockholders or making changes to provisions that are intended to protect all stockholders by requiring the affirmative vote of at least 66-2/3% of the total voting power to amend the key provisions of the ParentCo Certificate of Incorporation;

• Blank Check Company . The amendment will eliminate provisions specific to Iris’s status as a blank check company that will serve no purpose following the consummation of the Business Combination; and

• Corporate Opportunity . The removal of the corporate opportunity doctrine provisions would ensure that directors, officers and controlling stockholders will not be able to take advantage of opportunities beneficial to Liminatus for themselves without first disclosing the opportunity to the Liminatus board of directors and giving the Liminatus board of directors the opportunity to decline the opportunity on behalf of Liminatus.

#### Required Vote for Approval
The approval of the ParentCo Charter Proposal requires the affirmative vote of a majority of the votes cast by stockholders present in person or represented by proxy and entitled to vote thereon at the Special Meeting (which would include presence by virtual attendance at the Special Meeting). An abstention will be counted towards the quorum requirement but will not count as a vote cast at the Special Meeting. A broker non-vote will neither be counted towards the quorum requirement (as we believe the ParentCo Charter Proposal will be considered as non-dis